In particular, they found that the sensitivity of PET/MRI in HER2-positive tumors and the specificity in HER2-negative lesions were excellent, meaning that tumor disappearance was well identified in HER2-positive cases, while the residual disease was easily detected in HER2-negative cases [45]. This evidence concerns the gene ERBB2 and neoplasm.